Institute of Biophysics and Cell Engineering

http://ibp.org.by/  

Biomedical cell product "Mesenchymal stem cells"

COUNTRY OF ORIGIN

Belarus

IDENTIFIER

BO4356

PUBLISHED

2021-10-20

LAST UPDATE

2021-10-22

DEADLINE

Linked profile in other language
Responsible
Alena Кniazeva
+375 17 251 5357
kniazeva@ibp.org.by
Summary
The Institute has developed a biomedical cell product "Mesenchymal stem cells" and methods cell therapy of a wide range of human diseases in surgery, rheumatology, dentistry, urology, traumatology, infectology, etc. with its application. The Institute offers services for the treatment of diseases using the developed biomedical cell product under an outsourcing agreement.
Description
The biomedical cell product (BCP) is represented by mesenchymal stem cells (MSC) of an adult with typical morphology and phenotype. The main properties of MSCs that are valuable for their clinical use are high paracrine and immunomodulatory activity, the ability to self-renewal, and multilinear differentiation potential.

The biomaterial for the production of BCP is adipose tissue containing 2–5% of native MSCs, which is 10–1000 times higher than in the corresponding fraction of adherent bone marrow cells. The active proliferation of MSCs in vitro makes it possible to obtain a cell dose sufficient for successful clinical use.

MSCs of adipose tissue has an immunomodulatory effect, suppressing the activity of almost all cells of the immune system.

MSCs are capable of induced in vitro differentiation in adipogenic, osteogenic, chondrogenic, endothelial, myogenic, and neurogenic directions, which determines the areas of clinical use of BCPs based on them. The ability of MSCs to interact with other cells, both in vitro and in vivo, through the production of paracrine factors, exerting immunomodulatory, anti-inflammatory, trophic effects and stimulating angiogenesis is of great importance for clinical efficacy.

Methods of cell therapy with the use of MSCs in the treatment of many chronic diseases have been developed, which is manifested by tissue regeneration, elimination of the inflammatory reaction, and restoration of microcirculation.

The Institute offers services for the treatment of diseases using the developed biomedical cell product "Mesenchymal stem cells" under an outsourcing agreement.
Advantages and Innovations
The use of MSC in clinical practice increases the effectiveness of existing treatment methods, does not cause complications and side effects.
Stage of development
Already on the market
Funding source
State budged
IPR status
Secret know-how
Sector group
Healthcare

Client information

Type
R&D institution
Year established
1973
NACE keywords
M.72.11 - Research and experimental development on biotechnology
Q.86.90 - Other human health activities
Already engaged in transnational cooperation
Yes
Additional comments
Over the past 10 years, the Institute has carried out a number of international contracts and agreements within the framework of the Framework Programs of the European Union, as well as with leading research centers, foundations, societies:
FP7-HEALTH-2007-4.1-8 «Promotion and facilitation of international cooperation with Eastern European and Central Asian Countries» (EECAlink, Nr. 223359), 2009-2011;

UNESCO № IAP 3240246593/011/027-Minsk « Science Academies in the Central and Eastern Europe and their Role in Knowledge-based Society», 2010-2011;

FP7-PEAPLE-2012-IRSES «Development of Nanotechnology based Biosensors for Agriculture» (PIRSES-GA-2012-318520), 2012-2016;

FP7-PEAPLE-2012-IRSES «EU-Belarus-Russia Network in Nanomaterials-Driven Anti-Cancer Gene Therapy» (PIRSES-GA-2012-316730), 2013-2017;

FP7-PEOPLE-2011-IIF-299194 «Optical real-time imaging of inhibitory GABAA receptors activity using chimeric GABA channel subunit» («ImagingGABA» Nr 299194) 2013-2015;

«INNOVIMMUNE: Baltic Platform for Innovative Immunotherapies», Nr 19806/2016,2016-2018;

NAWA IAP «Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz» (№ PPI/APM/2018/1/00007/U/001) 2019-2020;

H2020-MSCA-RISE-2017 «Novel 1D photonic metal oxide nanostructures for early stage cancer detection» («CanBioSe», Nr 778157) 2018-2021:

The International Organization for Neurochemistry (ISN); Takeda Science Foundation; The Karpilo-Landau Society; Swiss National Science Foundation; University of Eastern Finland; World Federation of Scientists to Support Research, etc.
Languages spoken
English
Russian

Information about partnership

Type of partnership considered
Outsourcing agreement
Type and role of partner sought
Consumers interested in receiving services for the treatment of diseases using the developed biomedical cell product "Mesenchymal stem cells" within the framework of an outsourcing agreement.
Type and size of partner sought
251-500
SME 11-50
SME 51-250

Attachments

Количество уникальных просмотров в одной сессии: 84
Статистика ведется с 20.10.2021 17:42:23